Paracetamol
Acetaminophen (US) / Paracetamol (rest of world)
The world's most trusted painkiller hides a surprisingly dark metabolic secret.
Billions of doses a year. One narrow safety window.
Key Facts
- 1First synthesised in 1877, but ignored for over 60 years
- 2Taken by an estimated 600 million people annually worldwide
- 3The leading cause of acute liver failure in the developed world
- 4Its exact mechanism of pain relief is still debated today
- 5Just 7.5 grams (15 extra-strength tablets) can cause fatal liver damage
The Problem
Why This Molecule Was Needed
In the mid-19th century, pain relief was crude and dangerous. Physicians relied on opium, willow bark, and coal-tar derivatives with alarming side effects. The coal-tar era produced two promising antipyretics, acetanilide (1886) and phenacetin (1887), but both carried serious risks. Physicians desperately needed something that could reduce fever and ease pain without poisoning the blood or destroying the kidneys.
Paracetamol was actually synthesised in 1877 by Harmon Northrop Morse, but the compound sat unstudied for decades. It was hiding in plain sight: the body's own active metabolite of both acetanilide and phenacetin, circulating in patients' bloodstreams all along, unrecognised.
The Discovery
How It Happened
First synthesis
Harmon Northrop Morse synthesises paracetamol at Johns Hopkins, but the compound is not tested in humans.
Found in urine, then forgotten
Joseph von Mering tests paracetamol clinically but incorrectly concludes it causes methemoglobinemia, confusing it with p-aminophenol. This error delays adoption by half a century.
Rediscovery by Brodie and Axelrod
Brodie and Axelrod at the NIH discover that paracetamol is the actual active metabolite of acetanilide, responsible for its antipyretic effect.
First commercial sale as Tylenol
McNeil Laboratories launches "Tylenol Elixir for Children" in the United States, making paracetamol available as a standalone medicine for the first time.
Liver toxicity pathway uncovered
Mitchell, Jollow, and colleagues demonstrate that a reactive metabolite (later confirmed as NAPQI) causes hepatic necrosis when glutathione is depleted by overdose, explaining the narrow therapeutic window.
The Molecule
Up Close
Tap any region or group card to explore key structural features.
The Takeaway
Metabolic fate determines the therapeutic window
Paracetamol teaches a fundamental lesson in medicinal chemistry: a molecule's safety is not just about what it does at the target, but about what the body does to the molecule. The same CYP enzymes that clear the drug at low doses generate a lethal metabolite at high doses. Understanding metabolic fate is not optional; it is the difference between a medicine and a toxin.
Ready to learn the science behind drug design?
MedChemify covers molecular interactions, pharmacodynamics, and pharmacokinetics in depth, showing how real drugs are discovered and optimised.
Start Learning Free